Implementing Screening Guidelines for Preeclampsia Prevention in a Birth Center

Abstract

The aim of the project was to identify women at risk for developing preeclampsia who present for birth center care in order to initiate preventative treatment and retain them within the birth center practice. Birth center patients with preeclampsia disqualify for birth center care requiring hospital transfer. The target population consisted of pregnant women choosing birth center care with certified nurse midwives. Quality improvement method was utilized. Over 5-weeks, patients with 12 to 28 weeks' gestation were screened for preeclampsia risk factors; patients with high risk for preeclampsia initiated low-dose aspirin (LDA). All patients were evaluated for preeclampsia diagnosis up to 2 weeks postpartum. Outcomes were evaluated through chart audits. Screening for preeclampsia risk significantly increased LDA use. Preeclampsia screening did not statistically reduce incidences of preeclampsia but did show a moderate reduction. Use of LDA did not statistically reduce preeclampsia diagnoses but had a large reduction effect. Screening for preeclampsia in birth center patients results in increased use of LDA and potentially decreased rates of hospital transfer. Implementing preeclampsia screening is cost-effective and allows for increased patient retention.

The model of screening for preeclampsia in the second and third trimesters of gestation

“…PE risk factor screening significantly increases the use of low-dose aspirin does not statistically reduce the diagnosis of pe but has a significant reduction effect [8]. However, a combined first-trimester screening test (maternal factors, mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor) as recommended by the Fetal Medicine Foundation (FMF) and approved by the International Federation of Gynecology and Obstetrics (FIGO).…”

Pelaksanaan Skrining Preeklamsia Selama Kehamilan : A Scoping Review

“…Deteksi preeklamsia pada usia kehamilan lanjut Pada usia kehamilan 12 sampai 28 minggu ibu hamil diskrining untuk faktor risiko preeklamsia, pasien dengan risiko tinggi untuk preeklamsia memulai terapi aspirin dosis rendah (LDA) (Giles, 2020).…”